×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
BCDA – biocardia, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
BCDA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/20
08:14 am
bcda
BioCardia and Japan PMDA Align on Acceptability of CardiAMP Clinical Data to Support Regulatory Approval in Ischemic Heart Failure [Yahoo! Finance]
Low
Report
BioCardia and Japan PMDA Align on Acceptability of CardiAMP Clinical Data to Support Regulatory Approval in Ischemic Heart Failure [Yahoo! Finance]
4/20
08:00 am
bcda
BioCardia and Japan PMDA Align on Acceptability of CardiAMP Clinical Data to Support Regulatory Approval in Ischemic Heart Failure
Medium
Report
BioCardia and Japan PMDA Align on Acceptability of CardiAMP Clinical Data to Support Regulatory Approval in Ischemic Heart Failure
4/2
10:38 am
bcda
BioCardia Files Request for Meeting With FDA to Discuss Accelerated Approval Pathway for CardiAMP® System in Ischemic Heart Failure [Yahoo! Finance]
Medium
Report
BioCardia Files Request for Meeting With FDA to Discuss Accelerated Approval Pathway for CardiAMP® System in Ischemic Heart Failure [Yahoo! Finance]
4/2
10:11 am
bcda
BioCardia Files Request for Meeting With FDA to Discuss Accelerated Approval Pathway for CardiAMP® System in Ischemic Heart Failure
Low
Report
BioCardia Files Request for Meeting With FDA to Discuss Accelerated Approval Pathway for CardiAMP® System in Ischemic Heart Failure
3/24
11:07 pm
bcda
BioCardia Inc (BCDA) Q4 2025 Earnings Call Highlights: Promising Clinical Results Amid ... [Yahoo! Finance]
Medium
Report
BioCardia Inc (BCDA) Q4 2025 Earnings Call Highlights: Promising Clinical Results Amid ... [Yahoo! Finance]
3/24
08:46 pm
bcda
BioCardia outlines imminent CardiAMP FDA submission and targets regulatory catalysts as trial data signals clinical benefit [Seeking Alpha]
Medium
Report
BioCardia outlines imminent CardiAMP FDA submission and targets regulatory catalysts as trial data signals clinical benefit [Seeking Alpha]
3/24
08:46 pm
bcda
BioCardia, Inc. (BCDA) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Medium
Report
BioCardia, Inc. (BCDA) Q4 2025 Earnings Call Transcript [Seeking Alpha]
3/24
04:05 pm
bcda
BioCardia Reports 2025 Business Highlights and Financial Results
Low
Report
BioCardia Reports 2025 Business Highlights and Financial Results
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/22
05:04 pm
bcda
Form 4 BioCardia, Inc. For: Apr 20 Filed by: Altman Peter
Low
Report
Form 4 BioCardia, Inc. For: Apr 20 Filed by: Altman Peter
4/20
08:00 am
bcda
Form 8-K BioCardia, Inc. For: Apr 20
Medium
Report
Form 8-K BioCardia, Inc. For: Apr 20
4/15
04:30 pm
bcda
Form 8-K BioCardia, Inc. For: Apr 10
Low
Report
Form 8-K BioCardia, Inc. For: Apr 10
4/2
09:00 am
bcda
Form 8-K BioCardia, Inc. For: Apr 02
Medium
Report
Form 8-K BioCardia, Inc. For: Apr 02
3/26
08:06 pm
bcda
Form 4 BioCardia, Inc. For: Mar 24 Filed by: Altman Peter
Low
Report
Form 4 BioCardia, Inc. For: Mar 24 Filed by: Altman Peter
3/24
04:32 pm
bcda
Form 8-K BioCardia, Inc. For: Mar 24
Medium
Report
Form 8-K BioCardia, Inc. For: Mar 24
3/24
04:06 pm
bcda
Form 10-K BioCardia, Inc. For: Dec 31
Low
Report
Form 10-K BioCardia, Inc. For: Dec 31
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/28
BioCardia Awarded New U.S. Patent Covering Helix System for Local Biotherapeutic Delivery of Autologous and Allogenic Cells to the Heart
52.7%
10/1 BioCardia Initiates Commercial Release of AVANCE Steerable Introducer Designed to Enhance Physician Control for Complex Cardiac Procedures 15.2%
7/25 BioCardia Signs Exclusive Development Agreement With AstraZeneca 14.8%
1/8 BioCardia Announces New U.S. Patent Covering CardiAMP Cell Therapy and Issuance of Two Asian Patents Covering Radial Artery Approach for Cardiac Cell and Gene Therapy Delivery 13.9%
7/30 Form CERT BioCardia, Inc. 13.7%
4/1 BioCardia Inc (OTCMKTS: BCDA) had its "buy" rating re-affirmed by analysts at Maxim Group. They now have a $9.00 price target on the stock. 9.9%
5/20 BioCardia Reports 2019 First Quarter Financial Results and Business Highlights 6.5%
3/12 BIOCARDIA ANNOUNCES TIMING FOR PRESPECIFIED DATA SAFETY MONITORING BOARD REPORT ON PIVOTAL CARDIAMP HEART FAILURE TRIAL 5.6%
10/8 BioCardia Receives CE Mark Renewal For Helix Biotherapeutic Delivery Catheter And Morph Guide Catheter Through May 2024 4.4%
2/17 BioCardia Inc (OTCMKTS: BCDA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 4.2%
10/1 BioCardia Initiates Commercial Release of AVANCE Steerable Introducer Designed to Enhance Physician Control for Complex Cardiac Procedures 15.2%
7/25 BioCardia Signs Exclusive Development Agreement With AstraZeneca 14.8%
1/8 BioCardia Announces New U.S. Patent Covering CardiAMP Cell Therapy and Issuance of Two Asian Patents Covering Radial Artery Approach for Cardiac Cell and Gene Therapy Delivery 13.9%
7/30 Form CERT BioCardia, Inc. 13.7%
4/1 BioCardia Inc (OTCMKTS: BCDA) had its "buy" rating re-affirmed by analysts at Maxim Group. They now have a $9.00 price target on the stock. 9.9%
5/20 BioCardia Reports 2019 First Quarter Financial Results and Business Highlights 6.5%
3/12 BIOCARDIA ANNOUNCES TIMING FOR PRESPECIFIED DATA SAFETY MONITORING BOARD REPORT ON PIVOTAL CARDIAMP HEART FAILURE TRIAL 5.6%
10/8 BioCardia Receives CE Mark Renewal For Helix Biotherapeutic Delivery Catheter And Morph Guide Catheter Through May 2024 4.4%
2/17 BioCardia Inc (OTCMKTS: BCDA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 4.2%
TOP News Decliners
8/2
BioCardia Announces Pricing of $10.0 Million Public Offering and Uplisting to Nasdaq
-64.3%
8/1 BioCardia Inc (OTCMKTS: BCDA) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -17.6%
7/23 Form S-1/A BioCardia, Inc. -14.6%
10/2 BioCardia Announces the Appointment of Two New Board Members -11.3%
9/20 BioCardia Inc (OTCMKTS: BCDA) is now covered by analysts at Dawson James. They set a "buy" rating and a $24.00 price target on the stock. -7.7%
9/19 Biocardia Inc (NYSE: BCDA) had its "buy" rating re-affirmed by analysts at Dawson James. -6.0%
4/30 Biocardia Announces FDA-Recommended Modifications to Primary Endpoint for Cardiamp Cell Therapy Heart Failure Trial to Support Marketing Approval -5.0%
8/6 Form 4 BioCardia, Inc. For: Jul 05 Filed by: STERTZER SIMON H -4.9%
5/9 Form 8-K BioCardia, Inc. For: May 08 -4.3%
3/31 BIOCARDIA ANNOUNCES POSITIVE DSMB RECOMMENDATION TO CONTINUE PHASE III PIVOTAL CARDIAMP HEART FAILURE STUDY, AS PLANNED -3.1%
8/1 BioCardia Inc (OTCMKTS: BCDA) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -17.6%
7/23 Form S-1/A BioCardia, Inc. -14.6%
10/2 BioCardia Announces the Appointment of Two New Board Members -11.3%
9/20 BioCardia Inc (OTCMKTS: BCDA) is now covered by analysts at Dawson James. They set a "buy" rating and a $24.00 price target on the stock. -7.7%
9/19 Biocardia Inc (NYSE: BCDA) had its "buy" rating re-affirmed by analysts at Dawson James. -6.0%
4/30 Biocardia Announces FDA-Recommended Modifications to Primary Endpoint for Cardiamp Cell Therapy Heart Failure Trial to Support Marketing Approval -5.0%
8/6 Form 4 BioCardia, Inc. For: Jul 05 Filed by: STERTZER SIMON H -4.9%
5/9 Form 8-K BioCardia, Inc. For: May 08 -4.3%
3/31 BIOCARDIA ANNOUNCES POSITIVE DSMB RECOMMENDATION TO CONTINUE PHASE III PIVOTAL CARDIAMP HEART FAILURE STUDY, AS PLANNED -3.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: